Sesen Bio, Inc. (SESN) News
Filter SESN News Items
SESN News Results
|Loading, please wait...|
SESN News Highlights
- For SESN, its 30 day story count is now at 2.
- Over the past 4 days, the trend for SESN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIO are the most mentioned tickers in articles about SESN.
Latest SESN News From Around the Web
Below are the latest news stories about SESEN BIO INC that investors may wish to consider to help them evaluate SESN as an investment opportunity.
CAMBRIDGE, Mass., November 07, 2022--Sesen Bio (Nasdaq: SESN) today reported operating results for the third quarter ended September 30, 2022, and provided a business update.
SESEN BIO, INC. (SESN) closed the most recent trading day at $0.56, moving +1.8% from the previous trading session.
Sesen Bio's (SESN) third-quarter earnings are likely to reflect the cost savings from the company's restructuring plans.
In the latest trading session, SESEN BIO, INC. (SESN) closed at $0.50, marking no change from the previous day.
SESEN BIO, INC. (SESN) closed at $0.50 in the latest trading session, marking a -1.81% move from the prior day.
SESEN BIO, INC. (SESN) closed at $0.39 in the latest trading session, marking a -0.43% move from the prior day.
Wave Therapeutics (WVE) provides a positive update from its ongoing phase Ib/IIa study evaluating one of its lead candidates, WVE-003, for Huntington's disease. Stock up.
Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.
Sesen Bio Inc (NASDAQ: SESN) and privately held Carisma Therapeutics Inc have entered into a merger agreement to combine the companies in an all-stock transaction. The combined company will operate under the Carisma Therapeutics moniker under the "CARM symbol" and is expected to have approximately $180 million of cash and cash equivalents, including $30 million from concurrent financing by Carisma, which is expected to fund the company through 2024. Sesen Bio suffered FDA rejection for its lead
CAMBRIDGE, Mass. & PHILADELPHIA, September 21, 2022--Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered